BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38235574)

  • 21. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway.
    Gao L; Chen M; Ouyang Y; Li R; Zhang X; Gao X; Lin S; Wang X
    Life Sci; 2018 Jun; 202():188-194. PubMed ID: 29625193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsa_circ_0063804 enhances ovarian cancer cells proliferation and resistance to cisplatin by targeting miR-1276/CLU axis.
    You J; Han Y; Qiao H; Han Y; Lu X; Lu Y; Wang X; Kai H; Zheng Y
    Aging (Albany NY); 2022 Jun; 14(11):4699-4713. PubMed ID: 35687899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
    Xiao M; Guo J; Xie L; Yang C; Gong L; Wang Z; Cai J
    Mol Cancer Res; 2020 Mar; 18(3):436-447. PubMed ID: 31722968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression.
    Zhao S; Wu L; Kuang Y; Su J; Luo Z; Wang Y; Li J; Zhang J; Chen W; Li F; He Y; Tao J; Zhou J; Xu X; Peng C; Chen X
    Int J Oncol; 2018 Dec; 53(6):2397-2408. PubMed ID: 30272281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [MiR-125b-5 suppresses ovarian cancer cell migration and invasion by targeted downregulation of CD147].
    Huang Z; Shen H; Deng H; Sun L; Qü B
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Sep; 42(9):1389-1396. PubMed ID: 36210713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.
    Xia X; Ma Q; Li X; Ji T; Chen P; Xu H; Li K; Fang Y; Weng D; Weng Y; Liao S; Han Z; Liu R; Zhu T; Wang S; Xu G; Meng L; Zhou J; Ma D
    BMC Cancer; 2011 Sep; 11():399. PubMed ID: 21933447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD147 in ovarian and other cancers.
    Yang H; Chen B
    Int J Gynecol Cancer; 2013 Jan; 23(1):2-8. PubMed ID: 23221648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.
    Stuckey A; Fischer A; Miller DH; Hillenmeyer S; Kim KK; Ritz A; Singh RK; Raphael BJ; Brard L; Brodsky AS
    BMC Cancer; 2011 Jul; 11():308. PubMed ID: 21781307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fucosylated CD147 enhances the autophagy in epithelial ovarian cancer cells.
    Hu Z; Cai M; Deng L; Zhu L; Gao J; Tan M; Liu J; Lin B
    Oncotarget; 2016 Dec; 7(50):82921-82932. PubMed ID: 27863372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells.
    Feng J; Chen X; Wang Y; Du Y; Sun Q; Zang W; Zhao G
    Mol Cell Biochem; 2015 Oct; 408(1-2):163-70. PubMed ID: 26112905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LncRNA KCNQ1OT1 accelerates ovarian cancer progression via miR-125b-5p/CD147 axis.
    Chen P; Sun LS; Shen HM; Qu B
    Pathol Res Pract; 2022 Nov; 239():154135. PubMed ID: 36191448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.